Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TSIG.com TIGI (formerly TSIG) -- Ignore unavailable to you. Want to Upgrade?

To: Phxphenom who wrote (29709)	6/1/1999 2:08:00 PM
From: The Swordsman	Respond to of 44908

BRIEF: INKP is a biopharmaceutical company with two late-stage clinical compounds: a purgative product for colonscopies and other procedures and uses; and a steriod molecule for trearment of ITP. For the six months ended 12/31/98, the Company reported no revenues. Net loss decreased 39% to $3.8M. Results reflect a Phase III clinical trial for the Company's drug candidate, and a $3.9M purchased research and development charge. PRELIMINARY: For the 3 months ended 03/31/1999, after tax earnings were -2,501. Inkine Pharmaceutical Co. QUARTERLY SUMMARY HISTORICAL QUARTERLY RESULTS(Thousands of U.S. Dollars) REVENUE 1996 1997 1998 1999 1st Qtr SEP 0 0 0 0 2nd Qtr DEC 0 0 0 0 3rd Qtr MAR 0 0 0 0 4th Qtr JUN 0 0 0 EPS (U.S. Dollars per share) 1st Qtr SEP -0.070 -0.130 -0.100 -0.090 2nd Qtr DEC -0.080 -0.130 -0.400 -0.080 3rd Qtr MAR -0.090 -0.130 -0.070 -0.110* 4th Qtr JUN -0.130 -0.120 -0.080 11/97, Name changed from Panax Pharmaceutical Company.